Trial
NCT03761953
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Staphylococcus Aureus Bacteremia
Intervention
Oritavancin Injection
Why stopped
COVID 19 pandemic
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-06